Medical therapeutics: From induction to scientific evolution

Perspectives in Biology and Medicine

Volumn 56, Issue 4, 2013, Pages 568-583

  Nunes, José Pedro Lopes ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CARDIOLOGY; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; ETHICS; EVIDENCE BASED MEDICINE; HUMAN; MASS COMMUNICATION; PATIENT CARE; PATIENT SAFETY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TRENDS;

CARDIOLOGY; CARDIOVASCULAR DISEASES; DIFFUSION OF INNOVATION; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SAFETY; PATIENT-CENTERED CARE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84899434604     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2013.0036     Document Type: Article

References (63)

1. Aithal, G. P., et al. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-19.
2. Azoulay, L., et al. 2012. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case-control study. BMJ 344:e3645.
3. Bacon, F. 1620. The new organon. Cambridge: Cambridge University Press, 2000.
4. Baigent, C., et al. 2005. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-78.
5. Barritt, D. W., and S. C. Jordan. 1960. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial. Lancet 1:1309-12.
6. Bauer, G. 1946. Thrombosis: Early diagnosis and abortive treatment with heparin. Lancet 1:447-54.
7. Bennett, C. L., et al. 2008. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-24.
8. Bensing, J. 2000. Bridging the gap: The separate worlds of evidence-based medicine and patient-centered medicine. Patient Educ Couns 39:17-25.
9. Bernard, C. 1865. Introduction à l'étude de la médecine expérimentale. Paris: Champs, 2008.
10. Bigger, J. T., Jr., et al. 1984. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69:250-58.
11. Chin, R., and B. Y. Lee. 2008. Principles and practice of clinical trial medicine. Amsterdam: Academic Press.
12. Choudhry, N. K., H. T. Stelfox, and A. S. Detsky. 2002. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287:612-17.
13. Confucius. 1979. The analects. London: Penguin.
14. CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-35.
15. Diabetes Care. 2013. Executive summary: Standards of medical care in diabetes-2013. Diabetes Care 36(suppl. 1):S4-S10.
16. Echt, D. S., et al. 1991. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-88.
17. Eddy, D. M. 1984. Variations in physician practice: the role of uncertainty. Health Aff (Millwood) 3:74-89.
18. Feyerabend, P. 1975. Against method. London: Verso, 2010.
19. Fischer, R. A. 1935. The design of experiments. New York: Hafner, 1971.
20. Freedman, B. 1987. Equipoise and the ethics of clinical research. N Engl J Med 317:141-45.
21. Gerstein, H. C., et al. 2008. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-59.
22. Goldacre, B. 2012. Bad pharma. London: Fourth Estate.
23. Grimshaw, J., et al. 1995. Developing and implementing clinical practice guidelines. Qual Health Care 4:55-64.
24. Hamburg, M. A., and F. S. Collins. 2010. The path to personalized medicine. N Engl J Med 363:301-4.
25. Harris, C. A., et al. 2011. The efficacy of HER2-targeted agents in metastatic breast cancer: A meta-analysis. Ann Oncol 22:1308-17.
26. Houschyar, K. S., et al. 2012. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: Results from a randomized clinical trial. BMC Med 10:54.
27. Hume, D. 1739-40. A treatise of human nature. London: Penguin, 1985.
28. Hume, D. 1748. An enquiry concerning human understanding. Oxford: Oxford Univ. Press, 2007.
29. Katz, M.H. 2006. Multivariable analysis. 2nd ed. Cambridge: Cambridge Univ. Press.
30. Kuhn, T. S. 1962. The structure of scientific revolutions. Chicago: Univ. of Chicago Press, 1996.
31. McLean, J. 1916. The thromboplastic action of cephalin. Am J Physiol 41:250-57.
32. McMurray, J. J., et al. 2012. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787-847.
33. Medeiros, R., et al. 2003. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: Glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8:156-61.
34. Mega, J. L., et al. 2009. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-62.
35. Meinert, C. L., et al. 1970. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19(suppl.):789-830.
36. Messerli, F. H. 2009. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 53:468-70.
37. Mihaylova, B., et al. 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 380:581-90.
38. Mill, J. S. 1843. A system of logic: Ratiocinative and inductive, being a connected view of the principles of evidence, and the methods of scientific investigation. London: John W. Parker.
39. Miranda, V. P., et al. 2009. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: A narrative review. Rev Port Cardiol 28:1099-119.
40. Moynihan, R. N., et al. 2013. Expanding disease definitions in guidelines and expert panel ties to industry: A cross-sectional study of common conditions in the United States. PLoS Med 10:e1001500.
41. Murray, D. W. G., et al. 1937. Heparin and the thrombosis of veins following injury. Surgery 2:163-87.
42. National Cholesterol Education Program (NCEP). 2001. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report. JAMA 285:2486-97.
43. Nissen, S. E., and K. Wolski. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-71.
44. Ofsthun, N., et al. 2003. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63:1908-14.
45. Packer, M., et al. 2001. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-58.
46. Patel, A., et al. 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-72.
47. Pfeffer, M. A., et al. 2009. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-32.
48. Pitt, B., et al. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-17.
49. Popper, K. R. 1935. The logic of scientific discovery. London: Routledge, 2002.
50. Regidor, D. L., et al. 2006. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17:1181-91.
51. Rothwell, P. M. 2005a. External validity of randomised controlled trials: "To whom do the results of this trial apply?" Lancet 365:82-93.
52. Rothwell, P. M. 2005b. Treating individuals 2. Subgroup analysis in randomised controlled trials: Importance, indications, and interpretation. Lancet 365:176-86.
53. Ruberman, W., et al. 1991. Ventricular premature complexes and sudden death after myocardial infarction. Circulation 64:297-305.
54. Russell, B. 1928. Sceptical essays. Oxford: Routledge, 2004. Sextus Empiricus. Outlines of skepticism, ed. J. Annas and J. Barnes. Cambridge: Cambridge Univ. Press, 2000.
55. Singh, A. K., et al. 2006. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085-98.
56. Slamon, D. J., et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-92.
57. Staffa, J. A., J. Chang, and L. Green. 2002. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-40.
58. Tonia, T., et al. 2012. Erythropoietin or darbepoetin for patients with cancer. Cochrane Datab Syst Rev 12:CD003407.
59. Trivers, R. 2011. The folly of fools. New York: Basic Books.
60. UK Prospective Diabetes Study (UKPDS) Group. 1998a. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-65.
61. UK Prospective Diabetes Study (UKPDS) Group. 1998b. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-53.
62. Vedula, S. S., et al. 2009. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 361:1963-71.
63. Watkins, P. B., and R. W. Whitcomb. 1998. Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-17.